Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.

Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, Conway PM, Stroebel BM, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2015 Jan 1;584:362-7. doi: 10.1016/j.neulet.2014.11.013. Epub 2014 Nov 13.

PMID:
25445365
2.

A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR.

CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.

PMID:
25373630
3.

Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease.

Danielyan L, Beer-Hammer S, Stolzing A, Schäfer R, Siegel G, Fabian C, Kahle P, Biedermann T, Lourhmati A, Buadze M, Novakovic A, Proksch B, Gleiter CH, Frey WH, Schwab M.

Cell Transplant. 2014;23 Suppl 1:S123-39. doi: 10.3727/096368914X684970. Epub 2014 Oct 9.

PMID:
25302802
4.

Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.

Fine JM, Forsberg AC, Renner DB, Faltesek KA, Mohan KG, Wong JC, Arneson LC, Crow JM, Frey WH 2nd, Hanson LR.

Brain Res. 2014 Jul 29;1574:96-104. doi: 10.1016/j.brainres.2014.05.048. Epub 2014 Jun 10.

PMID:
24928620
5.

Intranasal insulin to treat and protect against posttraumatic stress disorder.

Frey WH 2nd.

J Nerv Ment Dis. 2013 Jul;201(7):638-9. doi: 10.1097/NMD.0b013e318298302e. Review. No abstract available.

PMID:
23817163
6.

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.

Freiherr J, Hallschmid M, Frey WH 2nd, Brünner YF, Chapman CD, Hölscher C, Craft S, De Felice FG, Benedict C.

CNS Drugs. 2013 Jul;27(7):505-14. doi: 10.1007/s40263-013-0076-8. Review.

7.

Intranasal delivery of insulin via the olfactory nerve pathway.

Renner DB, Svitak AL, Gallus NJ, Ericson ME, Frey WH 2nd, Hanson LR.

J Pharm Pharmacol. 2012 Dec;64(12):1709-14. doi: 10.1111/j.2042-7158.2012.01555.x. Epub 2012 Jul 4.

PMID:
23146033
8.

Intranasal treatment of central nervous system dysfunction in humans.

Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schiöth HB, Benedict C.

Pharm Res. 2013 Oct;30(10):2475-84. doi: 10.1007/s11095-012-0915-1. Epub 2012 Nov 8. Review.

9.

Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.

Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd.

Drug Deliv Transl Res. 2012 Jun;2(3):160-8. doi: 10.1007/s13346-011-0050-2.

PMID:
25786865
10.

Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.

Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, Pelleg A, Andrews A, Sparley KA, Krogh KM, Frey WH, Hanson LR.

Exp Brain Res. 2012 Jun;219(3):381-90. doi: 10.1007/s00221-012-3101-0. Epub 2012 May 1.

PMID:
22547371
11.

Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

Wolf DA, Hanson LR, Aronovich EL, Nan Z, Low WC, Frey WH 2nd, McIvor RS.

Mol Genet Metab. 2012 May;106(1):131-4. doi: 10.1016/j.ymgme.2012.02.006. Epub 2012 Feb 10.

PMID:
22420937
12.

Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway.

Renner DB, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2012 Apr 4;513(2):193-7. doi: 10.1016/j.neulet.2012.02.037. Epub 2012 Feb 22.

PMID:
22387067
13.

Intranasal delivery of growth differentiation factor 5 to the central nervous system.

Hanson LR, Fine JM, Hoekman JD, Nguyen TM, Burns RB, Martinez PM, Pohl J, Frey WH 2nd.

Drug Deliv. 2012 Apr;19(3):149-54. doi: 10.3109/10717544.2012.657720. Epub 2012 Feb 22.

PMID:
22353012
14.

Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states.

Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC.

Mol Pain. 2012 Jan 11;8:3. doi: 10.1186/1744-8069-8-3. Retraction in: Mol Pain. 2014;10:20.

15.

Brain insulin signaling and Alzheimer's disease: current evidence and future directions.

Schiöth HB, Craft S, Brooks SJ, Frey WH 2nd, Benedict C.

Mol Neurobiol. 2012 Aug;46(1):4-10. doi: 10.1007/s12035-011-8229-6. Epub 2011 Dec 29. Review.

16.

Intranasal treatment of neurodegenerative diseases and stroke.

Gomez D, Martinez JA, Hanson LR, Frey WH 2nd, Toth CC.

Front Biosci (Schol Ed). 2012 Jan 1;4:74-89. Review.

PMID:
22202044
17.

Insulin to treat Alzheimer's disease: just follow your nose?

Schiöth HB, Frey WH, Brooks SJ, Benedict C.

Expert Rev Clin Pharmacol. 2012 Jan;5(1):17-20. doi: 10.1586/ecp.11.70.

PMID:
22142155
18.

Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats.

Liu Z, Li Y, Zhang L, Xin H, Cui Y, Hanson LR, Frey WH 2nd, Chopp M.

Neurobiol Dis. 2012 Feb;45(2):804-9. doi: 10.1016/j.nbd.2011.11.004. Epub 2011 Nov 15.

19.

Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke.

Akpan N, Serrano-Saiz E, Zacharia BE, Otten ML, Ducruet AF, Snipas SJ, Liu W, Velloza J, Cohen G, Sosunov SA, Frey WH 2nd, Salvesen GS, Connolly ES Jr, Troy CM.

J Neurosci. 2011 Jun 15;31(24):8894-904. doi: 10.1523/JNEUROSCI.0698-11.2011.

20.

Motor end plate innervation loss in diabetes and the role of insulin.

Francis GJ, Martinez JA, Liu WQ, Zochodne DW, Hanson LR, Frey WH 2nd, Toth C.

J Neuropathol Exp Neurol. 2011 May;70(5):323-39. doi: 10.1097/NEN.0b013e318215669a.

PMID:
21487310
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk